❮ Return to Blog

Are Weight-Loss Drugs Causing Soaring Yogurt Sales?

Are Weight-Loss Drugs Causing Soaring Yogurt Sales?

Estimated reading time: 0 minutes

A New Favorite Snack

Americans have a new favorite snack food: Low-sugar Greek yogurt.

Sales in this segment have grown from $1.9 billion to $2.2 billion over the past year, according to data from yogurt company Chobani, citing Nielsen data. That’s an increase of nearly 18%, blowing overall yogurt sales (+9%) out of the water.

Weight-Loss Is Yogurt’s Gain

So what’s behind this sudden love for dairy? Greek yogurt can be an attractive option for health-conscious consumers looking for high in protein and low in sugar. But what else is new?

After all, cutting out sugar isn’t a new health trend. In 2023, 72% of Americans reported wanting to limit or cut sugar from their diet, according to the International Food Information Council.

Here’s what has changed: This recent spike of hunger for a healthy snack also coincided with the rising popularity of weight-loss drugs Ozempic and Wegovy, which have helped their manufacturer, Novo Nordisk (NVO), become one of Europe’s most valuable companies.

As the drugs’ popularity skyrocketed, food companies and retailers noted changes in shopping and consumption behavior. Walmart (WMT), for example, made headlines last year for suggesting weight-loss drugs changed its customers’ grocery shopping habits.

So low-sugar Greek yogurt may have benefited from this change in behavior as well.

SoFi Securities (Hong Kong) Limited and its affiliates (SoFi HK) may post or share information and materials from time to time. They should not be regarded as an offer, solicitation, invitation, investment advice, recommendation to buy, sell or otherwise deal with any investment instrument or product in any jurisdictions. Keep in mind that investing involves risk, and past performance of an asset never guarantees future results or returns. It’s important for investors to consider their specific financial needs, goals, and risk profile before making an investment decision.
SoFi HK does not make any warranties about the completeness, reliability and accuracy of this information and will not be liable for any losses and/or damages in connection with the use of this information.
The information and materials may contain hyperlinks to other websites, we are not responsible for the content of any linked sites. The information and analysis provided through hyperlinks to third party websites, while believed to be accurate, cannot be guaranteed by SoFi HK. These links are provided for informational purposes and should not be viewed as an endorsement. The risk involved in using such hyperlinks shall be borne by the visitor and subject to any Terms of Use applicable to such access and use.
Any product, logos, brands, and other trademarks or images featured are the property of their respective trademark holders. These trademark holders are not affiliated with SoFi HK or its Affiliates. These trademark holders do not sponsor or endorse SoFi HK or any of its articles.
Without prior written approval of SoFi HK, the information/materials shall not be amended, duplicated, photocopied, transmitted, circulated, distributed or published in any manner, or be used for commercial or public purposes.


About SoFi Hong Kong

About SoFi Hong Kong

SoFi – Invest. Simple.


SoFi Hong Kong is the All-in-One Super App with stock trading, robo advisor and social features. Trade over 15,000 US and Hong Kong stocks in our SoFi App now.